• Explore /
  • Poster
  • / Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).

Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).

Abstract Video & Slides Poster

Authors

null

Joerg Krueger

The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

Joerg Krueger , Henrique N. S. Bittencourt , Susana Rives , Andre Baruchel , Barbara De Moerloose , Christina Peters , Peter Bader , Jochen Buechner , Nicolas Boissel , Hidefumi Hiramatsu , Karen Thudium , Prasanthi Sanjeevi , Marina White , Lamis K. Eldjerou , Adriana Balduzzi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Leukemia/Lymphoma

Clinical Trial Registration Number

NCT03123939

Citation

J Clin Oncol 38: 2020 (suppl; abstr 10518)

DOI

10.1200/JCO.2020.38.15_suppl.10518

Abstract #

10518

Poster Bd #

405

Abstract Disclosures

Similar Posters

First Author: Michael Dickinson

First Author: Jessica Hochberg

First Author: Karen Thudium Mueller

First Author: Andrew Charles Dietz